Drugs / CHF6563
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04104646 | Dec 2020 → Dec 2021 | neonatal abstinence syndrome | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF6563 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04104646 ↗ |
| Known as | buprenorphine | “This was a randomised, multicentre, double-blind, double-dummy, parallel-group, controlled study of CHF6563 (non-ethanolic buprenorphine) sublingual solution.” NCT04104646 ↗ |